EFFECTS OF PATIENT-CENTERED PHARMACEUTICAL CARE ON DRUG THERAPY AND HEALTH -RELATED QUALITY OF LIFE AND MEDICATION ADHERENCE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
Phase 4
Recruiting
- Conditions
- major depressive disorderMDD
- Registration Number
- TCTR20220701001
- Lead Sponsor
- /A
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 326
Inclusion Criteria
1. Diagnosed as major depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V), 2. Treated with antidepressants for at least 2 weeks, 3. Take medicine by himself, 4. Thai who can communicate and read Thai language, 5. Follow-up date is within 4 to 5 weeks.
Exclusion Criteria
1. Treated with other treatment i.e. CBT or ECT, 2. Diagnosed as other psychiatric disorders i.e. anxiety disorder schizophrenia, 3.Cognitive impairment (TMSE<=23), 4.Diagnosed as other chronic diease and are not stable, 5. Can not contact via a telephone, 6. Can not complete the questionnaire at the first time
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Drug therapy-related quality of life at 4-5 weeks after Intervention Patient-Reported Outcomes Measure of Pharmaceutical Therapy for Quality of Life (PROMPT-QoL)-modified,Medication adherence at 4-5 weeks after Intervention MTB-Thai,Health-related quality of life at 4-5 weeks after intervention EQ-5D-5L
- Secondary Outcome Measures
Name Time Method Depression symptoms at 4-5 weeks after Intervention 9Q